IGC Pharma, Inc. (IGC) stock

IGCNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/309% above fair value

$0.18−0.01 (-4.61%)

Close on Nov 13, 2026Market cap $18.20MP/E –Yield –

IGC Pharma price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

IGC Pharma's price to sales ratio was 18.1× on Nov 11, 2026, against 26.5× a year earlier. Over the last 5 years it ranged from 12.7× to 154.8×, with a median of 23.2×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	18.1×	−5.3
2025	Dec 31, 2025	23.4×	+1.6
2024	Dec 31, 2024	21.8×	+8.5
2023	Dec 29, 2023	13.3×	−11.6
2022	Dec 30, 2022	24.9×	−129.9
2021	Dec 31, 2021	154.8×	+105.6
2020	Dec 31, 2020	49.1×	+45.2
2019	Dec 31, 2019	4.0×	+1.7
2018	Dec 31, 2018	2.3×	+2.2
2017	Dec 29, 2017	0.0×	+0.0
2016	Dec 30, 2016	0.0×	+0.0
2015	Dec 31, 2015	0.0×	−0.0
2014	Apr 30, 2014	0.0×	+0.0
2013	Dec 31, 2013	0.0×	−0.0
2012	Dec 31, 2012	0.0×	–